Tuesday, October 27, 2020 3:10:07 PM
I don't think anything is wrong except weak demand due to market selloff.
Also have to remember now the company has to send data to FDA to get
and answer which will be next year. A lot of people dont want to wait that long for results.
Also have to remember now the company has to send data to FDA to get
and answer which will be next year. A lot of people dont want to wait that long for results.
Recent AKBA News
- Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/28/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:24:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:05:53 AM
- Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/04/2026 08:05:00 PM
- Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology • GlobeNewswire Inc. • 05/04/2026 12:00:00 PM
- Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:13:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:12:53 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/15/2026 08:08:50 PM
- Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 • GlobeNewswire Inc. • 04/13/2026 12:00:00 PM
- Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:06:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:05:32 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:48:09 PM
- Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors • GlobeNewswire Inc. • 04/01/2026 08:05:00 PM
- Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:55:46 PM
- Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Akebia Therapeutics posts mixed Q4 results as revenue beats expectations despite EPS miss • IH Market News • 02/26/2026 03:57:19 PM
- Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook • IH Market News • 02/26/2026 03:48:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:04:39 PM
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
